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MicroRNAs (miRNAs) are recognized as being central
players in many biological processes and cellular pathways.
Their roles in disease have been highlighted ﬁrst by
observation of their aberrant expression proﬁles in human
tumors, and then by in vitro and in vivo functional studies in
transformed cells and model organisms. One of the most
commonly observed features of miRNAs in malignancies is
a defect in their production. Although several causes may
be associated with this phenomenon, such as upstream
oncogenic/tumor-suppressor defects and alterations in the
miRNA-processing machinery, epigenetic inactivation is
the prime suspect. The number of miRNAs with putative
growth-inhibitory functions undergoing promoter CpG
island hypermethylation in human cancer is growing fast
and more detailed biological studies are necessary. The
recognition of miR-124a and miR-34b/c as bona ﬁde tumor-
suppressor miRNAs undergoing DNA methylation-asso-
ciated silencing in a wide spectrum of human neoplasms is a
good starting point to be followed by other candidate
miRNAs. Most importantly, even at this early stage, the
transcriptional repression of miRNAs by hypermethylation
of their corresponding promoter loci seems to be a common
feature of all human tumors. This will have translational
consequences for the management of the disease.
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miRNAs: Processing, targets and transport
Non-coding RNAs (ncRNAs) were formerly considered
to be transcriptional noise, a byproduct of RNA
polymerase during the synthesis of functional RNA.
However, more than 90% of the human genome is
transcribed in a network of overlapping transcripts
without protein-coding capacity (Birney et al., 2007).
Moreover, ncRNA sequences and their secondary
structures are known to be subject to purifying selection;
the evolution of ncRNAs is not consistent with
neutralist explanations, thereby indicating that there is
selective pressure on them (Ponjavic et al., 2007).
ncRNAs are involved in different processes, including
not only those involved in protein synthesis (transfer
and ribosomal RNA), but also gene regulation, X-
chromosome inactivation (Xu et al., 2007) and telomer-
ase maintenance (Azzalin et al., 2007).
The most widely studied class of ncRNAs are
microRNAs (miRNAs), which are small ncRNAs
of B22-nt and are involved in post-translational
gene silencing by controlling mRNA translation into
proteins. It has been predicted that miRNAs regulate
the translation rate of more than 60% of protein-coding
genes (Friedman et al., 2009), and so participate in the
regulation of all cellular processes. Like mRNAs,
miRNAs are mainly transcribed by RNA polymerase-
II (Lee et al., 2004), although miRNA synthesis is
known to occur by RNA polymerase-III in those
miRNAs that reside near tRNA, Alu and mammalian-
wide interspersed sequences (Borchert et al., 2006).
RNA polymerase-II synthesizes a primary transcript
called pri-miRNA. The primary transcripts are long,
poly-(A)-tailed and capped species measuring several
kilobases. This transcript is processed by Drosha, a
ribonuclease-III protein (Lee et al., 2003), in collabora-
tion with DGCR8 (DiGeorge Syndrome Critical Region
Gene-8), the microprocessor protein (Han et al., 2006)
responsible for anchoring the pri-miRNA in the com-
plex. The processing of the pri-miRNA produces a 70-
nt-long molecule (Gregory et al., 2004), named pre-
miRNA, which migrates to the cytoplasm by using the
nuclear export protein Exportin-5 (XPO5) (Yi et al.,
2003). In the cytoplasm, the pre-miRNA is released in a
GTP-dependent manner and processed by Dicer
(a ribonuclease-III protein) in a complex with TRBP,
a double-stranded RNA-binding protein, to produce the
functional 22-nt-long miRNA (Hutva ´ gner et al., 2001),
which targets the mRNA. The B22-nt molecules are
loaded by the Dicer–TRPB complex into a member of
the Argonaute (Ago) Protein Subfamily to form the
RNA-induced silencing complex (RISC). These Ago
proteins are the catalytic components of the RISC
(Liu et al., 2004). The miRNA biosynthesis pathway is
summarized in the Figure 1.
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www.nature.com/oncThe genes targeted by the miRNAs are deﬁned by
complementary base pairs between the miRNA loaded
into the complex and, more often, the 30-untranslated
(UTR) region of the mRNA. The complementarity
between the miRNA and the targeted mRNA is
imperfect, the seed region of the miRNA (nucleotides
2–8) being essential to associate the miRNA with its
target mRNA (Lai, 2002; Lewis et al., 2003). Usually,
the 30UTR region of the mRNA is bound to multiple
miRNAs, improving the repressive effect of the miRNA
machinery (Grimson et al., 2007). mRNA cleavage is
one of the mechanisms by which miRNA regulates gene
expression. In this mechanism, the miRNAs act as small
interference RNAs (siRNAs), another type of ncRNA
produced by DICER from double-stranded RNA
sequences, mostly of exogenous origin. siRNAs direct
RNA cleavage through the RNA interference pathway
in extensive base pairing that is complementary between
the siRNA and the targeted mRNA (Plasterk, 2002).
The entrance of the miRNA in the RNA interference
pathway depends on the degree of complementarity
between the miRNA and the targeted mRNA
(Hutva ´ gner and Zamore, 2002). However, almost none
of the miRNA described was highly complementary to
its targeted sequence in the mRNA, preventing its
entrance into the RNA interference pathway (Elbashir
et al., 2001). In fact, the disruption of protein synthesis
in the ribosomes through inhibition of translational
initiation is the predominant mechanism of gene
silencing mediated by miRNAs. The RISC-bound
mRNAs localize in the processing bodies (P bodies) in
the cytoplasm, where they accumulate or are degraded
(Pillai et al., 2005). AU-rich elements (AREs) in the
30UTR of unstable mRNAs dictate their degradation
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Figure 1 The miRNA biosynthesis pathway from the nucleus to the cytosol. Ago, Argonaute protein; DGCR8, DiGeorge Syndrome
Critical Region Gene-8; miRNA, microRNA; ORF, open reading frame; TAR-binding protein; UTR, untranslated region;
XPO5, exportin-5; TRBP.
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Oncogene(Shaw and Kamen, 1986). miRNAs and Dicer are
involved in this mechanism of mRNA turnover. Many
miRNAs present a complementary sequence to the ARE
sequence characteristic of unstable mRNAs, the co-
operation between miRNA, Dicer and Ago proteins,
and ARE-binding proteins being essential for mRNA
decay (Jing et al., 2005).
Although gene silencing is the most thoroughly
studied role of miRNAs, the capability to upregulate
gene transcription during cell-cycle arrest has been
described; miRNA369-3 and let-7 oscillate between the
ability to repress and activate, depending on the cell
cycle. In proliferating cells, they repress the translation
of their target genes, whereas in cell arrest, which is
often the step preceding cell differentiation, they
promote activation (Vasudevan et al., 2007). Another
example of miRNA-mediated activation of mRNA
translation is the case of miR-10a (Ørom et al., 2008).
This miRNA enhances ribosomal protein synthesis by
binding to the 50UTR of the target mRNAs. The major
tumor-suppressor genes, p53 and RB, negatively reg-
ulate ribosome synthesis (Ruggero and Pandolﬁ, 2003),
and a very well known oncogene, MYC, positively
regulates protein production (Boon et al., 2001). As for
the described genes, miR-10a is involved in tumor
progression (Ørom et al., 2008). miRNAs are known to
target proteins directly. miRNAs can act as direct
inhibitors of ribonucleoprotein activity in an miRNA-
mediated silencing process called decoy. miR-328
interacts directly, independently of the Ago protein,
with the heterogeneous ribonucleoprotein (hnRNP) E2.
This interaction prevents the translational repression by
hnRNP E2 of CEBPA mRNA, a key regulator of
myeloid differentiation to granulocytes. Downregula-
tion of miR-328 allows the hnRNP E2 inhibition of
myeloid differentiation and thus, tumor progression
(Eiring et al., 2010). siRNAs have the ability to direct
gene silencing by heterochromatin formation. RNA-
induced transcription silencing is a mechanism described
in yeast (Verdel et al., 2004). The RNA-induced
transcription silencing complex recruits histone methyl-
transferases after siRNA loading, directing heterochro-
matin formation in the DNA locus.
miRNAs circulate in the bloodstream in a very stable
form; different mechanisms have been proposed to
explain the high stability of the circulating RNA in an
RNase-rich environment. Under normal conditions,
many cell types, such as B- and T-cells, mast cells and
reticulocytes, have the capacity to produce exosomes,
which are small membrane vesicles that are released into
the extracellular matrix with the plasma membrane.
Tumoral cells in melanoma are also known to produce
exosomes (Mears et al., 2004). The exosomes carry
proteins, mRNA and miRNA. The mRNA present in
the exosomes can be translated in the recipient cells,
suggesting a functional role for the miRNA. This
mechanism of RNA delivery is called ‘exosomal shuttle
RNA’ and may constitute a way by which the donor
cell regulates protein production in the recipient cell
(Valadi et al., 2007). In this paper, the authors found
121 miRNAs in the exosomes produced by mast
cells. Taking into account that every miRNA has the
potential to interfere with up to 200 mRNAs (Krek
et al., 2005), the regulatory capacity of the miRNAs
present in the exosomes may modulate up to 24000
mRNAs. More recently, it has been found that most of
the circulating miRNA in plasma is conﬁned to protein
complexes rather than membrane vesicles. These pro-
teins, like exosomes, protect miRNA from degradation,
there being at least two different populations of
circulating RNA. The ribonucleoprotein complex con-
tains Ago-2, the protein that mediates RNA silencing in
the RISC, suggesting that cells release functional
silencing complexes into the circulation to modulate
gene expression in the recipient cells (Arroyo et al.,
2011). Cell–cell communication can be mediated by
direct contact between the donor and the recipient cells
by gap junction intercellular connections. miRNAs can
pass from one cell to the other by these junctions and
modulate the gene expression of the targeted genes in
the receptor cell (Lim et al., 2011). These authors
showed the exchange of miRNAs between bone marrow
stromal cells and metastatic breast cancer cells by
this mechanism; speciﬁc miRNAs target CXCL12, a
chemokine involved in cell communication and signal
transduction, cell proliferation is reduced and cells enter
quiescence, suggesting a role for miRNAs in the
dormancy of breast cancer cells in the bone marrow
and explaining the recurrence of metastatic breast
cancer from the bone marrow many years after primary
tumor elimination (Willis et al., 2010). Figure 2 sum-
marizes the different mechanisms by which miRNAs
regulate gene expression.
The regulation of gene expression by miRNAs, their
role in targeting different genes and their capacity to
move between cells illustrate the complexity of tran-
scriptome regulation in the cells. In addition, RNA
editing increases this complexity by generating new
molecules from existing ones (reviewed by Bass, 2002).
RNA editing occurs by the deamination of adenosines
to inosines, performed by adenosine deaminase acting
on RNA enzymes (ADAR), mostly within the non-
coding regions of the transcripts. The newly generated
nucleotide base pairs have cytosine instead of thymidine,
promoting the synthesis of new proteins from a single
open reading frame (Burns et al., 1997) and altering
miRNA targeting by editing of the miRNAs or the
mRNAs (Borchert et al., 2009). Moreover, the role of
pseudogenes in miRNA homeostasis has been described.
Pseudogenes are commonly considered to be non-
functional genomic loci and to have no biological
relevance, although preservation of the nucleotide
sequences suggests that they are under selective pressure.
Pseudogenes can be transcribed or not, and those that
are transcribed show a high complementarity with the
protein-coding gene from the 50 to the 30UTR. Taking
into account that miRNAs commonly regulate gene
silencing by 30UTR sequence complementarity, pseudo-
genes may act to regulate miRNA activity on the coding
gene by competing for the miRNA molecules present in
the cell. This mechanism of miRNA regulation has been
modeled by studying PTEN (tumor-suppressor gene)/
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OncogenePTENP1 (PTEN pseudogene) expression levels in
tumoral cell lines (Poliseno et al., 2010). The authors
demonstrated the role of PTEN transcripts in modulat-
ing miRNA targeting by examining PTENP1 levels.
This study provides a new perspective on transcriptional
regulation. Considering the genomic rearrangements,
copy-number alterations and translocations that many
cancer cells suffer and that give rise to altered levels of
the transcripts, changes in the tumoral cell phenotype
can be due not only to the protein alteration itself, but
also to global RNA deregulation by altered competition
for miRNAs (Poliseno et al., 2010).
miRNAs: Cancer involvement and deregulation
mechanisms
Cancer development involves genetic and epigenetic
alterations that give rise to an uncontrolled overgrowth
of cells (Jones and Baylin, 2007; Berdasco and Esteller,
2010). Research has tended to focus on coding genes and
the proteins they produce, classifying them as onco-
genes, if they promote cell growth, or tumor-suppressor
genes, if they prevent overgrowth. With the discovery of
miRNAs in Caenorhabditis elegans in the late 1990s
(Fire et al., 1998) and their regulatory role in gene
expression, a new front in cancer research was initiated.
As with classical genes, the non-coding loci in the
DNA (ncRNAs) can be subjected to genetic and
epigenetic alterations. These alterations modify the
expression proﬁle of the ncRNAs and thus alter the
mechanism they regulate. Chromosome abnormalities
(deletions, translocations, copy-number alterations),
DNA mutations and epigenetic deregulation of the
ncRNAs or the genes involved in their biogenesis have
been described in tumor progression. The ﬁrst associa-
tion between miRNA and cancer development was
described in chronic lymphocytic leukemia with chro-
mosome 13q14 deletion. This deletion deregulates
miR-15 and miR-16 (Calin et al., 2002). Most of the
targets of these two miRNAs are involved in cell growth
and cell cycle (for example, Anxa2 and Cdc2), apoptosis
(Grp78 and Bcl2), and oncogenes and tumor-suppressor
genes (Wt1 and Rab8B) (Calin et al., 2008). Surpris-
ingly, miRNAs are frequently located in fragile regions
of the chromosomes as has been shown in ovarian and
breast carcinomas and melanomas (Calin et al., 2004;
Zhang et al., 2006). miR-16 is also involved in the
mRNA decay of tumor necrosis factor-a (Jing et al.,
2005) by ARE sequence binding in the 30UTR of the
mRNA. This suggests that a single miRNA involved in
the regulation of multiple mRNAs can use different
mechanisms to achieve gene silencing: not only basepair
complementary to speciﬁc sequences in the targeted
genes, but also recognition of the ARE instability signal.
Mutations of the miRNA sequences can also disrupt
their regulatory role. Mutations in the primary tran-
scripts of miR-15a and miR-16-1 are responsible for
their reduced expression levels in chronic lymphocytic
leukemias (Calin et al., 2005). Polymorphisms have been
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Figure 2 Mechanisms by which miRNAs regulate gene expression within a cell and in neighboring cells. Ago, Argonaute protein;
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Oncogenedescribed in a set of miRNAs in non-small cell lung
cancer and a single single-nucleotide polymorphism in
has-mir-196a2-3p is associated with survival in patients
with non-small cell lung cancer, probably owing to a
defect in binding to the target gene (Hu et al., 2008).
let-7 is one of the most widely studied miRNA
families in cancer. Alterations of let-7 function have
been described in several human cancer types, such as
lung cancer (Takamizawa et al., 2004), colorectal cancer
(Akao et al., 2006), head and neck cancer (Yu et al.,
2011), and ovarian cancer (Wendler et al., 2011). It acts
mainly as a tumor-suppressor miRNA. On the one
hand, the members of this family negatively regulate
cell-cycle-related genes such as RAS or cyclins (Johnson
et al., 2005). Mutations or alterations of the expression
proﬁle of these oncogenes are involved in cancer
development. On the other hand, the let-7 miRNA
family inﬂuences apoptosis owing to its negative
regulation of the Fas gene (Wang et al., 2011). Fas is
a death receptor in peripheral T-cells, which is involved
in activation-induced cell death (AICD) in the presence
of the Fas ligand, a member of the tumor necrosis factor
cytokine family (Krueger et al., 2003). In cervical
carcinomas as compared with normal tissue, let-7 is
overexpressed and, as a consequence, the level of Fas
gene expression is reduced (Das et al., 2000; Lee et al.,
2008). In this case, the let-7 miRNA family acts as an
oncomiRNA (tumor-promoting miRNA).
miRNA biosynthesis is also subjected to extracellular
signaling. Under mitogenic signals, the mitogen-acti-
vated protein kinase (MAPK) Erk mediates the phos-
phorylation of TRBP, one of the components of the
DICER1 complex. TRBP phosphorylation enhances
miRNA expression by increasing the stability of the
biosynthesis complex (Paroo et al., 2009). Surprisingly,
under tumorigenic signals, only miRNAs involved in cell
growth promotion are upregulated when the MAPK/
Erk pathway is activated, and let-7 miRNA expression
levels, which are mainly involved in cell growth
suppression, are reduced. let-7 downregulation has
been shown under type-I collagen activation of the
transforming growth factor-b1-mediated expression of
MT1–MMP (membrane type-1-matrix metalloprotei-
nase) and Erk pathway activation in pancreatic ductal
adenocarcinoma (Dangi-Garimella et al., 2011). This
mechanism modulates the metastatic capacity of the
tumoral cells by enhancing the expression of metallo-
proteinases, which are proteins involved in collagen
degradation, a key process for promoting cell invasion
through the extracellular matrix (Ottaviano et al., 2006),
and let-7 downregulation (Dangi-Garimella et al., 2011).
Alterations in the genes involved in miRNA expres-
sion can disrupt the correct function of these miRNAs.
Overexpression of the oncogenic miRNA miR-17-92
cluster has been reported in human cancer (Volinia
et al., 2006). This miRNA family is regulated by
c-Myc, a transcriptional factor overexpressed in
multiple human cancers (Chang et al., 2008). Over-
expression of c-Myc activates miR-17-92 cluster expres-
sion. This family regulates the gene silencing of many
genes involved in cell cycle and proliferation. The miR-
17-92 cluster confers resistance to cell senescence and
apoptosis by silencing several tumor-suppressor genes
such as PTEN (Olive et al., 2009) and p21 (Hong et al.,
2010). Angiogenesis is a key step in tumor development
and metastasis, providing nutrients and oxygen to
overgrowing cells. The miR-17-92 cluster confers a
metastatic capacity on tumoral cells by inhibiting Tsp1
(anti-angiogenic thrombospondin-1) and CTGF (con-
nective tissue growth factor), which are genes involved
in angiogenesis (Dews et al., 2006).
Once transcribed, miRNAs are processed and ex-
ported from the nucleus to the cytoplasm. Alterations in
the processing machinery can also lead to deregulation
of functional miRNAs. Reduction of the expression
levels of Drosha and Dicer has been described in ovarian
cancer patients, leading to a downregulation of mature
miRNAs (Merritt et al., 2008). Germline mutations in
the DICER1 gene have been described in familial
ovarian and pulmonary neoplasm (Rio Frio et al.,
2011), and kidney neoplasm (Bahubeshi et al., 2010). An
miRNA family, miR-103/107, targets Dicer to down-
regulate its translation into the protein and attenuate
global miRNA synthesis. This mechanism creates a
feedback relationship taking into account that miR-103/
107 are both generated by and regulators of Dicer,
producing a downscaling of Dicer levels but not their
complete depletion, maintaining a basal level to regulate
the miRNA pathway (Martello et al., 2010). Over-
expression of the miR-130/107 family in breast cancer is
associated with epithelial–mesenchymal transition and
metastasis due to the downregulation of miR-200 levels.
The miR-200 family regulates the silencing of ZEB1/
ZEB2, which are genes involved in the epithelial–
mesenchymal transition (Burk et al., 2008).
Latent infection by Epstein–Barr virus is associated
with the development of human cancers such as Burkitt
lymphoma, Hodgkin lymphoma and pharyngeal carci-
nomas (Pagano, 2002). The viral genome encodes its
own miRNAs, identiﬁed in human B-cells infected by
Epstein–Barr virus (Pfeffer et al., 2004). miR-BART6-
5p, one of the miRNAs encoded by the virus, targets
Dicer and suppresses its expression, altering global
miRNA patterns in the infected cells (Iizasa et al., 2010).
TARBP2, one of the components of the DICER1
complex, presents frameshift mutations that cause
diminished protein expression levels in sporadic and
hereditary colorectal carcinomas. This reduced expres-
sion causes a defect in pre-miRNA processing and
promotes tumor progression (Melo et al., 2009). XPO5
is the protein in charge of miRNA export from the
nucleus to the cytoplasm. Inactivating mutations in the
XPO5 gene appear in human carcinomas with satellite
instability; these mutations trap pre-miRNA in the
nucleus and deregulate the mature miRNA pattern in
cancer cells (Melo et al., 2010).
miRNAs: The impact of aberrant DNA methylation proﬁles
One of the most common causes of the loss of tumor-
suppressor miRNAs in human cancer is the silencing of
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Oncogenetheir primary transcripts by CpG island promoter
hypermethylation (Saito et al., 2006; Lujambio et al.,
2007, 2008; Toyota et al., 2008; Huang et al., 2009). In
cancer, cells undergo global hypomethylation of the
DNA (Feinberg and Vogelstein, 1983). This contributes
to genome instability and the transcription of silenced
transposable sequences, promoting chromosomal rear-
rangements and genome disruption, a characteristic
feature of tumoral cells. However, the CpG islands
of the promoter regions of the tumor-suppressor
genes undergo DNA hypermethylation, leading to gene
silencing and promotion of cancer development (Jones
and Baylin, 2007; Berdasco and Esteller, 2010). The
DNA methylation proﬁle of tumors can be used as a
signature to deﬁne tumor type, clinical prognosis and
treatment response (Esteller, 2008; Rodrı´guez-Paredes
and Esteller, 2011). miRNAs transcribed from CpG
islands undergo DNA methylation-associated repression
with a similar chromatin context to coding genes, such
as binding of the transcriptional repressor methyl-CpG-
binding domain proteins (Lujambio et al., 2007;
Urdinguio et al., 2010), and a histone modiﬁcation
proﬁle associated with silencing, such as in the case of
loss of acetylation of histones H3 and H4 (Lujambio
et al., 2007; Toyota et al., 2008). A similar chromatin-
repressive environment has been described for other
ncRNAs, such as transcribed-ultraconserved regions,
which also undergo promoter CpG island hypermethy-
lation in cancer cells (Lujambio et al., 2010). Figure 3
illustrates aberrant DNA methylation patterns that
occur in tumoral cells.
Epigenetic silencing of the tumor-suppressor miR-
124a by aberrant DNA hypermethylation of the color-
ectal cancer cell line HCT-116 leads to cyclin-D kinase-6
(CDK6) overexpression, its target. Transfection of the
tumoral cell line with miR-124a diminishes CDK6
protein levels and retinoblastoma (Rb) phosphorylation,
one of the targets of the kinase (Lujambio et al., 2007).
Both proteins are involved in cell-cycle progression.
Rb is an antiproliferative tumor-suppressor gene that,
when phosphorylated by CDK6, diminishes its anti-
proliferative activity (Grossel and Hinds, 2006). Hyper-
methylation of this miRNA has also been observed in
glioblastoma multiforme (Silber et al., 2008), gastric
cancer (Ando et al., 2009), hematopoietic malignancies
(Agirre et al., 2009; Roman-Gomez et al., 2009), cervical
cancer (Wilting et al., 2010) and hepatocellular carcino-
ma (Furuta et al., 2010).
miR-145 is a well-known tumor-suppressor miRNA
that is downregulated in many human cancers owing to
aberrant DNA methylation of its promoter and/or
p53 mutations (Suh et al., 2011). This miRNA is a
pluripotency repressor; it regulates OCT, SOX2 and
KLF4 gene silencing in human embryonic stem cells,
genes required for cell self-renewal and pluripotency
maintenance (Xu et al., 2009). In fact, they are three of
the four factors known to acquire de novo pluripotency
(Takahashi and Yamanaka, 2006). Reprogramming to
pluripotency resembles the de-differentiation process
that cancer cells undergo during tumor formation.
In acute myeloid leukemia, the oncogene c-kit is
overexpressed in 60–80% of patients (Kindler et al.,
2004). miR-193a has been described as a key tumor-
suppressor miRNA that targets c-kit and, thus, prevents
cell overgrowth and promotes cell differentiation. This
miRNA is regulated by DNA methylation and its
aberrant silencing by DNA hypermethylation has
been described in acute myeloid leukemia cell lines
(Gao et al., 2011).
miR-335 was identiﬁed in a set of miRNAs involved
in the suppression of breast cancer metastasis to the
lungs and bone (Tavazoie et al., 2008). It was found to
inhibit metastasis by targeting the genes involved in cell
invasion and migration such as the transcription factor
SOX4 and the extracellular matrix protein tenascin-C.
This miRNA undergoes genetic deletion and promoter
hypermethylation silencing in metastatic cell popula-
tions derived from primary breast tumors. Cells that
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Figure 3 Aberrant DNA methylation patterns in human cancer. Heavily methylated repetitive sequences undergo hypomethylation
events in transformed cells that might cause genome instability (right panel), whereas unmethylated promoter CpG islands of coding
genes and miRNAs with tumor-suppressor features become hypermethylated and silenced in cancer cells (left panel).
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Oncogeneundergo miR-335 silencing in the population have a
selective advantage over the others, acquiring metastatic
capacity and colonizing new tissues (Png et al., 2011).
The genetic and epigenetic silencing of this miRNA have
been observed in ovarian cancer samples, and its
deletion is correlated with the malignant progression
of breast and ovarian tumors. miR-129-2 is another
miRNA involved in SOX4 silencing and it is also
regulated by promoter methylation. Aberrant miR-192-
2 DNA hypermethylation has been found in endome-
trial (Huang et al., 2009), colorectal (Bandres et al.,
2009) and gastric cancer (Shen et al., 2010).
miR-199a expression is regulated by DNA methyla-
tion of the locus from which it is transcribed (Cheung
et al., 2011). Downregulation of this miRNA owing to
aberrant DNA hypermethylation of its promoter and its
association with invasive properties of the tumoral cells
have been described in gastric (Ueda et al., 2010),
ovarian (Yin et al., 2010) and testicular (Cheung et al.,
2011) tumors. This miRNA regulates the silencing of
many genes involved in tumor progression. In testicular
cancer, it targets PODXL, an anti-adhesive protein that
inhibits cell–cell interaction, a key feature of the cells
that acquire an invasive phenotype in the primary tumor
(Cheung et al., 2011).
Nuclear factor-kB is a transcription factor that
regulates the proinﬂammatory response. Its activation
is linked to cancer development by its role in the
regulation of the secretion of cytokines and chemokines
by the immune cells in the tumoral microenvironment.
Its activation is regulated by the IkB kinases (IKKs) by
phosphorylation and further degradation of the nuclear
factor-kB inhibitor, IkBa. This cascade promotes the
translocation of nuclear factor-kB to the nucleus, where
it promotes the gene expression of the inﬂammatory
cytokines involved in cell proliferation. In most cancer
cells, the IKKs and, for instance, nuclear factor-kB are
constitutively active (Chen et al., 2007). miR-199a
regulates the post-transcriptional silencing of IKKb,
one of the members of the IKK complex. Aberrant
downregulation of the miRNA activates the IKK
pathway by aberrant translation of IKKb. This pro-
motes the secretion of proinﬂammatory molecules
characteristic of tumor development (Chen et al., 2008).
miR-34 is a tumor-suppressor miRNA family regu-
lated by the transcriptional factor p53 (Tarasov et al.,
2007) and DNA methylation (Lujambio et al., 2008;
Toyota et al., 2008; Tsai et al., 2011). p53 is one of the
best studied tumor-suppressor genes; it is called the
‘guardian of the genome’ because it promotes apoptosis
under DNA damage. It regulates the expression of many
oncogenes such as c-Myc, Bcl2, and cell cytokines and
miRNAs involved in cell proliferation. Inactivation of
miR-34 members is a common feature of many tumor
types. Downregulation of miR-34 owing to p53 inacti-
vation or DNA hypermethylation of its promoter alters
the Notch pathway (Pang et al., 2010), which is involved
in the promotion of cell invasion (Bin Hafeez et al.,
2009) and apoptosis of cancer cells. One of the targets of
miR-34 is SIRT1, an oncogene that decreases the ability
of p53 to promote cell-cycle arrest by deacetylating the
protein. In this way, cells create a positive feedback loop
between p53 and miR-34 for tumor prevention mediated
by SIRT1 silencing (Yamakuchi et al., 2008). Altered
expression proﬁle of this miRNA family has been
described in gastric (Tsai et al., 2011), ovarian (Corney
et al., 2010), colorectal (Lujambio et al., 2008) and non-
small cell lung cancer (Gallardo et al., 2009). Promoter
CpG island hypermethylation for both miR-34b/c
(Lujambio et al., 2008; Toyota et al., 2008; Roman-
Gomez et al., 2009; Tsai et al., 2011) and miR-34a
(Lodygin et al., 2008; Chim et al., 2010; Corney et al.,
2010) represents a major mechanisms accounting for
the loss of these transcripts in human cancer.
Epigenetic silencing of miRNAs is also involved in the
acquisition of an invasive phenotype and the develop-
ment of metastasis (Lujambio and Esteller, 2009).
Treatment with the DNA methylation inhibitor 5-aza-
20-deoxycytidine and further analysis of miRNA expres-
sion arrays of metastatic cells from lymph node
metastasis of different human cancers showed cancer-
speciﬁc DNA hypermethylation of the CpG islands in
the promoter of three miRNAs, miR-148a, miR-9
family and miR-34b/c. Epigenetic silencing of these
miRNAs mediates the activation of metastatic genes
such as c-Myc, CDK6 and E2F3 (E2F transcription
factor-3, involved in the activation of the expression of
cyclins and other proliferative genes), targeted by miR-
34b/c downregulation, and TGIF2 (transforming
growth factor-b-induced factor-2), targeted by miR-
148a (Lujambio et al., 2008). Alterations in these
miRNAs have been described in many cancer types
such as breast (Lehmann et al., 2008), ovarian (Laios
et al., 2008) and pancreatic cancer (Omura et al., 2008).
Surprisingly, miR-9 has been described as an oncogene
owing to its role in E-cadherin silencing in hepatocel-
lular carcinomas promoting cell invasion (Tan et al.,
2010). This suggests the potential dual role of miRNA in
promoting or inhibiting tumoral progression, depending
on the tissue where they are expressed. Hypermethyla-
tion of the miR-9 family has also been reported
in hematopoietic malignancies (Roman-Gomez et al.,
2009) and renal cell carcinoma (Hildebrandt et al.,
2010). Recent reports have also indicated the presence of
hypermethylation-associated silencing of some miR-200
family members in cancer cells (Ceppi et al., 2010; Neves
et al., 2010; Vrba et al., 2010; Wiklund et al., 2010; Chen
et al., 2011). The miR-200 family has an important
epithelial–mesenchymal transition-regulatory activity in
which it directly targets and inhibits ZEB1 and ZEB2
(Hurteau et al., 2006; Park et al., 2008), transcriptional
repressors of E-cadherin, a cell adhesion protein crucial
for maintaining epithelial structure (Peinado et al.,
2007). Most importantly, the DNA methylation-
associated silencing of the miR-200 family is a dynamic
process that determines the evolving epithelial–mesench-
ymal transition phenotypes of colorectal and breast
tumors (Davalos et al., 2011).
Other important miRNAs disrupted by promoter
CpG island hypermethylation in human cancer include
miR-203, which targets ABL1 and is epigenetically
inactivated in hematopoietic malignancies (Bueno et al.,
Silencing of tumor-suppressor miRNAs in cancer
P Lopez-Serra and M Esteller
1615
Oncogene2008) and hepatocellular carcinoma (Furuta et al.,
2010); miR-181c, which targets the oncogenes NOTCH4
and K-RAS, and undergoes hypermethylation in gastric
tumors (Hashimoto et al., 2010); and let-7a-3 in ovarian
cancer with an inverse correlation with insulin-like
growth factor-II expression (Lu et al., 2007). The list
of miRNAs undergoing promoter CpG island hyper-
methylation in human cancer is rapidly expanding and a
recent epigenomic survey of 450000 CpG sites revealed
that among the 616 miRNAs printed in the micro-
array, 30–40 miRNAs underwent hypermethylation in
colorectal cancer cells (Sandoval et al., 2011):
As mentioned above, cell treatment with the DNA-
demethylating agent 5-aza-20-deoxycytidine and the
histone deacetylase inhibitor 4-phenylbutyric acid fol-
lowed by analysis of transcript expression proﬁles is a
common approach used to identify sequences controlled
by the epigenetic marks. Using this approach, the
epigenetic silencing of miRNA-127 in prostate and
bladder cancer described originally (Saito et al., 2006).
This miRNA belongs to an miRNA cluster but only
miR-127 presents a CpG island, being the only one
regulated by DNA methylation. Silencing of this
miRNA by DNA hypermethylation leads to cancer
progression owing to overexpression of its target, BCL6,
a key regulator of p53 expression.
miRNAs can be transcribed from intronic regions in
coding genes. Sometimes, the tumoral phenotype is
thought to be the cause of the aberrant hypermethyla-
tion of a given gene, but it is also due to the
downregulation of the miRNA it hosts. This is the case
of miR-342, which is transcribed from the EVL gene
(Grady et al., 2008). The EVL promoter is hypermethy-
lated in the early stages of colorectal adenocarcinomas
and as a consequence, the gene and the miRNA are both
downregulated. EVL is a gene involved in cell polarity
and cytoskeleton remodeling, and can affect cell
motility. The targets of miR-342 have not been
described. Another miRNA aberrantly methylated in
the early stages of colorectal cancer development is miR-
137 (Balaguer et al., 2010), which is also methylated in
oral cancer (Kozaki et al., 2008) and glioblastoma
multiforme (Silber et al., 2008). Among the targets of
this miRNA, we can highlight LSD-1 (lysine-speciﬁc
histone demethylase-1), a histone demethylase that has a
key role in the epigenetic regulation of gene expression;
CDK6 and E2F6, a transcription factor involved in
cell-cycle progression. In primary hepatocellular
tumors, aberrant hypermethylation of miR-1, a tumor-
suppressor miRNA targeting FoxP1, a ubiquitously
expressed transcription factor; MET (hepatocyte
growth factor receptor) and histone deacetylase-4 has
been described. Overexpression of these genes owing
to miRNA silencing promotes hepatocellular carcino-
genesis (Datta et al., 2008).
Considered from the opposite point of view, aberrant
DNA hypermethylation of tumor-suppressor genes can
be promoted by an altered miRNA expression proﬁle.
In hepatitis B virus-related hepatocellular carcinomas,
the levels of miRNA-152 are downregulated relative to
those in non-cancerous tissues. miR-152 downregulation
promotes the overexpression of DNA methyltransfer-
ase-1 (DNMT1), its target, and, as a consequence,
aberrant DNA hypermethylation. The relation of the
viral infection and the hypermethylation of the DNA is
the hepatitis B virus X protein (HBx), the inhibitor of
miR-152. This mechanism may also be involved in the
methylation of the hepatitis B virus genome, promoting
the survival of the virus in the host cells (Huang et al.,
2010). The miRNA-29 family is downregulated in lung
cancer. This family of miRNAs has sequence comple-
mentarity with the 30UTR of DNMTs 3a and 3b. These
two enzymes are frequently upregulated in lung cancer
and are associated with poor prognosis in patients.
An inverse correlation between DNMT-3a and -3b, and
the members of the miRNA-29 family has also been
noted. Enforced expression of these miRNAs restores
the normal DNA methylation proﬁle by silencing the
DNMTs, inducing the expression of tumor-suppressor
genes that are aberrantly methylated, and inhibiting
tumor growth in lung cancer cell lines and mice
(Fabbri et al., 2007).
Table 1 summarizes the best characterized miRNAs
dysregulated by DNA hypermethylation and the func-
tional consequences in tumoral cells.
miRNAs: Translational applications
From a clinical point of view, miRNAs have great
potential at the diagnostic and therapeutic levels.
Microarray technology offers the opportunity to deter-
mine the expression of thousands of miRNAs at the
same time, generating a very useful miRNA proﬁle
to determine the tumor type, patient prognosis
and treatment response. Microarray analysis highlights
a general downregulation of miRNAs in tumors when
compared with normal tissues (Lu et al., 2005);
furthermore, owing to the remarkable tissue speciﬁcity
of the miRNAs, they become a very useful tool for
deﬁning the origin of the tumor in poorly differentiated
cancers (Rosenfeld et al., 2008). In fact, a speciﬁc
miRNA signature is being used for cancer screening.
The prognosis and survival of patients depend on the
stage of the cancer when they are diagnosed. For this
reason, one of the most important issues in clinical
cancer research is to ﬁnd early biomarkers of the
tumorigenic process. In clear cell renal carcinoma, the
miRNA signature distinguishes between metastatic and
non-metastatic tumors. The 5-year survival rate of
patients with primary metastasis is 10% as compared
with 70–90% in non-metastatic patients (Heinzelmann
et al., 2011), the miRNA signature being a powerful tool
for early diagnosis. Moreover, analysis of circulating
tumor-derived miRNAs represents a non-invasive
means of diagnosing cancer (Kosaka et al., 2010). The
utility of altered miRNA levels in serum has been noted
in many cancer types. For example, serum levels of
miRNA-141 can distinguish people with prostate cancer
from healthy individuals (Mitchell et al., 2008). From an
epigenetic point of view, there is a DNA methylation
signature for human cancer metastasis (Lujambio et al.,
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lymph node metastatic cancer cells and tumors, and
found a relationship between speciﬁc miRNA hyper-
methylation patterns and the metastatic behavior of
tumors. The use of miRNA gene hypermethylation
to improve cancer diagnosis has been extended recently
to many types of biological ﬂuids, such as oral rinses
(Langevin et al., 2010), feces (Kalimutho et al., 2011) and
colorectal mucosal wash ﬂuids (Kamimae et al., 2011).
miRNAs not only have diagnostic but also thera-
peutic potential. Inactivation of tumor-promoting
miRNAs (Medina et al., 2010; Obad et al., 2011) or
restoration of tumor-suppressor miRNAs (Saito et al.,
2006; Lujambio et al., 2007, 2008) offers great prospects
for cancer treatment. Activation of hypermethylated
tumor-suppressor miRNAs can be accomplished by
using chromatin-modifying drugs such as DNA methy-
lation inhibitors. To date, two DNMT inhibitors, 5-
azacytidine and 5-aza-20-deoxycytidine, have been ap-
proved by the US Food and Drug Administration
(FDA) for the treatment of myelodysplastic syndromes
and acute myeloid leukemia (Rodrı´guez-Paredes and
Esteller, 2011). Thus, part of the clinical beneﬁt of these
drugs might relate to their capacity to hypomethylate
and reactivate previously silenced tumor-suppressor
miRNAs. Finally, it is worth mentioning the novel area
of reactivating miRNAs with low levels of expression
in human tumors (Melo et al., 2011). In this approach, a
small drug acts as a coactivator of the miRNA-
processing machinery, particularly the aforementioned
TRBP protein encoded by the TARBP2 gene,
to enhance the production of mature miRNAs (Melo
Table 1 Hypermethylated miRNAs in human cancer and their functional consequences
miRNA hyper-
methylated
Chromo-
some
Target Functional consequences Cancer type
miR-1 20 FoxP1 Transcriptional activation Hepatocarcinoma
MET Cell proliferation, angiogenesis, tumor cell invasion
HDAC4 Gene transcription alteration
miR-9-1 1 FGF family Cell proliferation Breast, ovarian, pancreas, hematological, renal
Claudin family Cell communication and growth
miR-9-3 15 E-cadherin Cell migration Colorectal, melanoma, head and neck
miR-34a 1 CD44 Cell communication and signal transduction Hematological, prostate, breast, renal,
Notch1 Transcriptional activation colorectal, ovarian
miR-34b/c 11 Notch1 Transcriptional activation Gastric, ovarian, lung, colon, melanoma,
c-Myc Transcriptional activation head and neck
Bcl2 Cell proliferation
SIRT1 Epigenetic gene silencing
miRNA-124a 20 CDK6 Cell-cycle deregulation Colon, gastric, hematological, cervical, liver,
glioblastoma
miR-127 14 BCL6 p53 downregulation and cell proliferation Prostate, bladder
miR-129-2 11 SOX4 Cell dedifferentiation and proliferation Gastric, endometrial, colorectal
miR-137 1 CDK6 Cell-cycle dysregulation Oral, colorectal, glioblastoma,
E2F6 Cell-cycle dysregulation
LSD-1 Gene transcription alteration
miR-145 5 OCT/SOX2/KLF4 Cell dedifferentiation Prostate
miR-148a 7 TGIF2 Invasive capacity Colorectal, melanoma, head and neck, breast
miR-129-2 11 SOX4 Cell dedifferentiation and proliferation Gastric, endometrial
miR-181c 19 Notch4 Transcriptional activation Gastric
K-Ras Signal transduction
miRNA-199a 19 PODXL Invasive capacity Testicular, ovarian
IKKb Proinﬂammatory molecules secretion
miR-200c 12 ZEB1/ZEB2 Epithelial–mesenchymal transition Colorectal, breast, lung
miR-141 12 ZEB1/ZEB2 Epithelial–mesenchymal transition Colorectal, breast, lung
miR-429 1 ZEB1/ZEB2 Epithelial–mesenchymal transition Colorectal, breast, lung
miR-203 14 ABL1 Cell communication and signal transduction Hematological, liver
miR-205 1 ZEB1/ZEB2 Epithelial–mesenchymal transition Bladder
miRNA-335 7 SOX4/TNC Cell dedifferentiation and proliferation Breast
miR-342 14 PDGFRA Cell proliferation Colorectal
RASA1 Cell proliferation
let-7a-3 22 IGF-II Cell communication and signal transduction Ovarian, breast
Abbreviation: miRNA, microRNA.
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compound, or similar ones, can override the silencing
belts imposed on the hypermethylated miRNAs, it is a
pharmacological strategy that merits further attention.
Final perspective
From the candidate miRNA approach to whole-
epigenome strategies, an increasing number of miRNAs
undergoing DNA methylation-associated silencing in
cancer cells have been described since the ﬁrst reported
instance in this area (Saito et al., 2006). Although the
functional tumor-suppressor roles and a rigorous
analysis of the promoter CpG island hypermethyla-
tion-related transcriptional repression have been accom-
plished for a few of them, such as miR-124a and
miR-34b/c, from initial observations (Lujambio et al.,
2007, 2008; Toyota et al., 2008) to subsequent indepen-
dent studies (that is, Ando et al., 2009; Furuta et al.,
2010; Va ´ zquez et al., 2010; Wilting et al., 2010), much
effort lies ahead of us. A good deﬁnition of the exact
transcription start sites for many of the new candidates
and a detailed characterization of their mRNA targets
are needed. Most importantly, further cell and mouse
models will be required to test their growth-inhibitory
function. However, even now, the epigenetic inactivation
of miRNAs with tumor-suppressor activities is recognized
as a major hallmark of human tumors, probably at the
same level as the promoter CpG island hypermethylation
of classical coding tumor-suppressor genes (Jones and
Baylin, 2007; Berdasco and Esteller, 2010). Their use as
biomarkers of the disease and as potential therapy targets
will develop and exciting developments in this area are
expected in the near future.
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